Moving towards the greener side: environmental aspects guiding pastoral mobility and impacting vegetation in the Dzungarian Gobi, Mongolia

Livestock grazing often intensifies around herder camps, which can lead to degradation, particularly in arid areas, where vegetation is scarce. In Mongolia, nomadic herders have covered long distances between camps and changed camps regularly for centuries. However, changing socioeconomics, rising livestock numbers, and climatic change have led to growing concerns over rangeland health. To understand travel mobility and livestock grazing patterns, we combined Global Positioning System tracking data of goats, remotely sensing pasture productivity, and ground-based vegetation characteristics in the Great Gobi B Strictly Protected Area, Mongolia. We assessed herder preferences for camp selection, followed 19 livestock herds over 20 months, determined use and nutrient contents of the most dominant plant communities, and estimated plant species richness, vegetation cover, and biomass within different grazing radii around camps. Biomass availability was key for herder decisions to move camps, but in winter, other factors like shelter from wind were more important. Camps were mainly located in Stipa spp. communities, agreeing with herder preferences for this highly nutritious species, and its dominance around camps. Herders changed their camp locations on average 9 times yearly, with a maximum distance of 70–123 km between summer and winter camps, and an average visitation period of 25–49 d per camp, depending on season. Small livestock spent > 13−17 h daily within a radius of 100 m from camp, and livestock use intensity decreased steeply with distance from camp but was remarkably similar around spring, autumn, and winter camps on the Gobi plains. However, we found little evidence for a corresponding gradient in plant species richness, biomass, and cover on the Gobi plains. The high mobility of local herders and the overriding impact of precipitation on pasture dynamics contribute to a sustainable vegetation offtake by livestock in the nonequilibrium rangelands of the Dzungarian Gobi.publishedVersio

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Moving towards the greener side: environmental aspects guiding pastoral mobility and impacting vegetation in the Dzungarian Gobi, Mongolia

Livestock grazing often intensifies around herder camps, which can lead to degradation, particularly in arid areas, where vegetation is scarce. In Mongolia, nomadic herders have covered long distances between camps and changed camps regularly for centuries. However, changing socioeconomics, rising livestock numbers, and climatic change have led to growing concerns over rangeland health. To understand travel mobility and livestock grazing patterns, we combined Global Positioning System tracking data of goats, remotely sensing pasture productivity, and ground-based vegetation characteristics in the Great Gobi B Strictly Protected Area, Mongolia. We assessed herder preferences for camp selection, followed 19 livestock herds over 20 months, determined use and nutrient contents of the most dominant plant communities, and estimated plant species richness, vegetation cover, and biomass within different grazing radii around camps. Biomass availability was key for herder decisions to move camps, but in winter, other factors like shelter from wind were more important. Camps were mainly located in Stipa spp. communities, agreeing with herder preferences for this highly nutritious species, and its dominance around camps. Herders changed their camp locations on average 9 times yearly, with a maximum distance of 70–123 km between summer and winter camps, and an average visitation period of 25–49 d per camp, depending on season. Small livestock spent > 13−17 h daily within a radius of 100 m from camp, and livestock use intensity decreased steeply with distance from camp but was remarkably similar around spring, autumn, and winter camps on the Gobi plains. However, we found little evidence for a corresponding gradient in plant species richness, biomass, and cover on the Gobi plains. The high mobility of local herders and the overriding impact of precipitation on pasture dynamics contribute to a sustainable vegetation offtake by livestock in the nonequilibrium rangelands of the Dzungarian Gobi

Outcome of Tyrosinaemia type III

Tyrosinaemia type III is a rare disorder caused by a deficiency of 4-hydroxyphenylpyruvate dioxygenase, the second enzyme in the catabolic pathway of tyrosine. The majority of the nine previously reported patients have presented with neurological symptoms after the neonatal period, while others detected by neonatal screening have been asymptomatic. All have had normal liver and renal function and none has skin or eye abnormalities. A further four patients with tyrosinaemia type III are described. It is not clear whether a strict low tyrosine diet alters the natural history of tyrosinaemia type III, although there remains a suspicion that treatment may be important, at least in infancy

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society